000			03622nam a22003615i 4500
001			81718
003			ES-MaUEC
005			20230207040343.0
007			cr nn 008mamaa
008			150302s2015 ne | s |||| 0|eng d
020			_a9789401797320
024	7		_a10.1007/978-94-017-9732-0 _2doi
050		4	_aQP552 _b.K564 2015
245	1	0	_aKinesins and Cancer _cedited by Frank Kozielski, FSB.
260			_aDordrecht, Netherlands _bSpringer _c2015
300			_a1 recurso en línea (X, 271 páginas) _b50 ilustraciones, 32 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPreface -- The kinesin superfamily -- The discovery and development of Eg5 inhibitors for the clinic -- Mechanism of action of Eg5 inhibitors -- Clinical trials of mitotic kinesin inhibitors -- Kif15; a useful target for anti-cancer therapy?.-Â{u4BF7}wn-regulating CENP-E activity: for better or for worse -- The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target.-Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy -- Chromokinesins in genome maintenance and cancer -- Kif14: a clinically relevant kinesin and potential target for cancer therapy -- Kinesin-8 members and their potential as biomarker or therapeutic target -- The kinesin-6 members MKLP1, MKLP2 and MPP -- Non-motor spindle proteins as cancer chemotherapy targets -- Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons -- Index.
520	3		_aThis interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development. Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future. The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER, asignarmaterias_11febrero
650		7	_aAnálisis clínicos _2embne _9138438
650		7	_aProteínas _2embne _9139861
650		7	_aCitología _2embne _9139477
700	1		_aKozielski, FSB, Frank _eeditor literario _994305 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-94-017-9732-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12903085 _b10-10-17 _c18-01-16
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gne _h0
945			_aQP552 .K564 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1157270x _z06-04-17
999			_c81718 _d81718 _x1